{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:13:18Z","timestamp":1790982798529,"version":"4.1.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/coc.0b013e3181845529","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T05:48:55Z","timestamp":1242884935000},"page":"238-244","source":"Crossref","is-referenced-by-count":11,"title":["Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma"],"prefix":"10.1097","volume":"32","author":[{"given":"Boris","family":"Guiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Cercueil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romaric","family":"Loffroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Ferrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Boulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Minello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bedenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Chauffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","article-title":"Primary liver cancer: worldwide incidence and trends.","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000.","volume":"94","author":"Parkin","year":"2001","journal-title":"Int J Cancer"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/j.gastro.2003.12.049","article-title":"Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.","volume":"126","author":"Sangiovanni","year":"2004","journal-title":"Gastroenterology"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1053\/j.gastro.2004.09.032","article-title":"Chemoembolization for hepatocellular carcinoma.","volume":"127","author":"Bruix","year":"2004","journal-title":"Gastroenterology"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival.","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","article-title":"Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.","volume":"46","author":"Varela","year":"2007","journal-title":"J Hepatol"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire.","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","article-title":"Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.","volume":"29","author":"Pelletier","year":"1998","journal-title":"J Hepatol"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.COC.0000020588.20717.BB","article-title":"Chemoembolization of hepatocellular carcinoma: results of a meta analysis.","volume":"26","author":"Geschwind","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"R14-3-20210128","first-page":"691","article-title":"Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.","volume":"1","author":"Dhingra","year":"1995","journal-title":"Clin Cancer Res"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00177262","article-title":"Pirarubicin (4\u2032-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A clinical phase II study.","volume":"8","author":"Scheithauer","year":"1990","journal-title":"Invest New Drugs"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0399-8320(04)95221-9","article-title":"Sustained clinical response of large hepatocellular carcinoma after chemoembolization with pirarubicin, amiodarone and lipiodol.","volume":"28","author":"Cercueil","year":"2004","journal-title":"Gastroenterol Clin Biol"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1574::AID-CNCR11>3.0.CO;2-8","article-title":"Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors.","volume":"88","author":"Ueno","year":"2000","journal-title":"Cancer"},{"key":"R18-3-20210128","first-page":"1973","article-title":"Anticancer and side effect of arterial subsegmental chemoembolization using cisplatinum\/pirarubicin lipiodol suspension (CTLS) for hepatocellular carcinoma [in Japanese].","volume":"20","author":"Inoue","year":"1993","journal-title":"Gan To Kagaku Ryoho"},{"key":"R19-3-20210128","first-page":"1303","article-title":"A clinical trial of transarterial chemoembolization for hepatocellular carcinoma using 4\u2032-o-tetrahydropyranyladriamycin.","volume":"17","author":"Izumi","year":"1990","journal-title":"Gan To Kagaku Ryoho"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00001813-200111000-00003","article-title":"Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma.","volume":"12","author":"Favoulet","year":"2001","journal-title":"Anticancer Drugs"},{"key":"R21-3-20210128","first-page":"1550","article-title":"Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.","volume":"53","author":"Munck","year":"1993","journal-title":"Cancer Res"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00686340","article-title":"A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.","volume":"29","author":"Robert","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"R23-3-20210128","first-page":"257","article-title":"Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo.","volume":"12","author":"Tapiero","year":"1986","journal-title":"Drugs Exp Clin Res"},{"key":"R24-3-20210128","first-page":"559","article-title":"Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines.","volume":"15","author":"Minemura","year":"1999","journal-title":"Int J Oncol"},{"key":"R25-3-20210128","first-page":"825","article-title":"Amiodarone-induced enhancement of doxorubicin and 4\u2032-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo.","volume":"46","author":"Chauffert","year":"1986","journal-title":"Cancer Res"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-3659(97)00127-2","article-title":"Stable lipiodolized emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolization.","volume":"50","author":"Yi","year":"1998","journal-title":"J Control Release"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1148\/radiographics.19.2.g99mr08399","article-title":"Chemoembolization of hepatic neoplasms: safety, complications, and when to worry.","volume":"19","author":"Gates","year":"1999","journal-title":"Radiographics"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma.","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.2006.09.8657","article-title":"Transcatheter and ablative therapeutic approaches for solid malignancies.","volume":"25","author":"Liapi","year":"2007","journal-title":"J Clin Oncol"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00268-004-6927-1","article-title":"Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice.","volume":"28","author":"Favoulet","year":"2004","journal-title":"World J Surg"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/hep.1840130308","article-title":"Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a western comparative study in 60 patients.","volume":"13","author":"Vetter","year":"1991","journal-title":"Hepatology"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","article-title":"Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.","volume":"131","author":"Takayasu","year":"2006","journal-title":"Gastroenterology"},{"key":"R34-3-20210128","first-page":"125","article-title":"Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients.","volume":"38","author":"Dumortier","year":"2006","journal-title":"Dig Liver Dis"},{"key":"R35-3-20210128","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/hep.1840190508","article-title":"Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors.","volume":"19","author":"Mondazzi","year":"1994","journal-title":"Hepatology"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1542-3565(05)00425-8","article-title":"Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.","volume":"3","author":"Biselli","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R37-3-20210128","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/1097-0142(20001201)89:11<2266::AID-CNCR15>3.0.CO;2-0","article-title":"How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system.","volume":"89","author":"Farinati","year":"2000","journal-title":"Cancer"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00535-005-1566-3","article-title":"Updated treatment approach to hepatocellular carcinoma.","volume":"40","author":"Llovet","year":"2005","journal-title":"J Gastroenterol"},{"key":"R39-3-20210128","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1478-3231.2006.001285.x","article-title":"Treatment and prognostic factors in patients with hepatocellular carcinoma.","volume":"26","author":"Martins","year":"2006","journal-title":"Liver Int"},{"key":"R40-3-20210128","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1046\/j.1365-2036.2003.01647.x","article-title":"Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment.","volume":"17","author":"Testa","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R41-3-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1148\/radiology.214.2.r00fe06349","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center.","volume":"214","author":"Vogl","year":"2000","journal-title":"Radiology"},{"key":"R42-3-20210128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1440-1746.2002.02664.x","article-title":"Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization.","volume":"17","author":"Lee","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R43-3-20210128","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/028418501127347278","article-title":"Palliative treatment of hepatocellular carcinoma by chemoembolization.","volume":"42","author":"Poyanli","year":"2001","journal-title":"Acta Radiol"},{"key":"R44-3-20210128","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/1097-0142(19950515)75:10<2427::AID-CNCR2820751007>3.0.CO;2-J","article-title":"Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience.","volume":"75","author":"Stefanini","year":"1995","journal-title":"Cancer"},{"key":"R45-3-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<50::AID-CNCR8>3.0.CO;2-I","article-title":"A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.","volume":"88","author":"Llad","year":"2000","journal-title":"Cancer"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.1840120422","article-title":"Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients.","volume":"12","author":"Calvet","year":"1990","journal-title":"Hepatology"},{"issue":"suppl","key":"R47-3-20210128","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1007\/BF00687112","article-title":"Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors.","volume":"31","author":"Hsieh","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"R48-3-20210128","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/1097-0142(19911115)68:10<2150::AID-CNCR2820681011>3.0.CO;2-F","article-title":"Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model.","volume":"68","author":"Ikeda","year":"1991","journal-title":"Cancer"},{"key":"R49-3-20210128","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00004836-199906000-00010","article-title":"Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors.","volume":"28","author":"Savastano","year":"1999","journal-title":"J Clin Gastroenterol"},{"key":"R50-3-20210128","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1007\/BF02100123","article-title":"Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization.","volume":"41","author":"Farinati","year":"1996","journal-title":"Dig Dis Sci"},{"key":"R51-3-20210128","article-title":"Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial).","author":"Llovet","year":"2007"},{"key":"R52-3-20210128","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-200906000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:47:30Z","timestamp":1786038450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-200906000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181845529","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}